Search results
Results From The WOW.Com Content Network
Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start a biotechnology company, Genentech. Although the two confidently assert that it was the first biotech company, others clearly came before, including Cetus Corporation which was founded in 1971.
Roche. F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But ...
Before you buy stock in Roche Ag, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Roche Ag wasn ...
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
At stake will be the weight-loss drugs market, which could become as large as $100 billion or more by the end of the decade. Roche's trailing-12-month revenue is $67.7 billion. While it won't be ...
Syntex. Laboratorios Syntex SA (later Syntex Laboratories, Inc.) was a pharmaceutical company formed in Mexico City in January 1944 by Russell Marker, Emeric Somlo, and Federico Lehmann to manufacture therapeutic steroids from the Mexican yams called cabeza de negro ( Dioscorea mexicana) and Barbasco ( Dioscorea composita ). [1]
Another weight-loss drug developer, Roche Holdings (OTC: RHHBY) fared better, with a 2.7% gain. Threat of a Viking invasion That rival is ambitious clinical-stage biotech Viking Therapeutics .